Search Grant Opportunities

Advancing Validated Drug Targets for Substance Use Disorders (R41/R42 - Clinical Trial Not Allowed)

ID: RFA-DA-22-018 • Type: Posted

Description

This Funding Opportunity Announcement (FOA) solicits grant applications from small business concerns (SBCs) to continue research projects with robustly validated targets for Substance Use Disorders (SUDs). This FOA will provide funding for projects entering at either assay development (AD), lead identification (LI), lead optimization (LO), or preclinical development (PCD) stages to allow for the ultimate goal of successfully completing Investigational New Drug-enabling activities.

Overview

Category of Funding
Education
Health
Funding Instruments
Grant
Grant Category
Discretionary
Cost Sharing / Matching Requirement
False
Source
On 7/29/21 the National Institutes of Health posted grant opportunity RFA-DA-22-018 for Advancing Validated Drug Targets for Substance Use Disorders (R41/R42 - Clinical Trial Not Allowed). The grant will be issued under grant program 93.279 Drug Abuse and Addiction Research Programs.

Timing

Posted Date
July 29, 2021, 12:00 a.m. EDT
Closing Date
Feb. 18, 2022, 12:00 a.m. EST Past Due
Last Updated
July 29, 2021, 2:59 p.m. EDT
Version
1
Archive Date
March 26, 2022

Eligibility

Eligible Applicants
Small businesses
Additional Info
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.

Contacts

Contact
National Institutes of Health
Contact Email
Email Description
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Contact Phone
(301) 402-2541

Documents

Posted documents for RFA-DA-22-018

Grant Awards

Grants awarded through RFA-DA-22-018

Incumbent or Similar Grants

Similar Active Opportunities

Open grant opportunities similar to RFA-DA-22-018